Literature DB >> 16198313

Over-expression of CD9 does not affect in vivo tumorigenic or metastatic properties of human prostate cancer cells.

Valerii Zvieriev1, Jia-Chi Wang, Mario Chevrette.   

Abstract

Expression of tetraspanin CD9 protein is downregulated in many tumors. CD9 over-expression also reduces the tumorigenicity of some human cancer cells. Here, we determined if exogenous expression of CD9 affects the properties of human prostate cancer cells. Highly metastatic prostate cancer cells PC-3M-LN4 over-expressing exogenous CD9 were orthotopically injected into the prostate of nude mice. CD9 expression was determined in tumors using PCR and Western immunoblotting techniques. Over-expression of CD9 increased invasiveness of prostate cancer cells in vitro. Animals injected with either parental PC-3M-LN4 or CD9-transfected cells developed tumor and harbored lymph node metastasis. There was no statistical difference in tumor growth between the two cell lines. CD9 did not suppress tumorigenic or metastatic properties of PC-3M-LN4 cells. Our data contrast with published results in other tumor types and likely indicate that other proteins (CD9 partners) are needed for CD9 full anti-tumorigenic action.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16198313     DOI: 10.1016/j.bbrc.2005.09.073

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  7 in total

Review 1.  Tetraspanins in cell migration.

Authors:  Xupin Jiang; Jiaping Zhang; Yuesheng Huang
Journal:  Cell Adh Migr       Date:  2015-06-19       Impact factor: 3.405

Review 2.  Tetraspanins as regulators of the tumour microenvironment: implications for metastasis and therapeutic strategies.

Authors:  S Detchokul; E D Williams; M W Parker; A G Frauman
Journal:  Br J Pharmacol       Date:  2014-12       Impact factor: 8.739

3.  Integrative transcriptomic and proteomic analysis reveals CD9/ITGA4/PI3K-Akt axis mediates trabecular meshwork cell apoptosis in human glaucoma.

Authors:  Junwei Yan; Xuejiao Yang; Xuefei Jiao; Xian Yang; Mingjin Guo; Yunqing Chen; Lu Zhan; Wenshi Chen
Journal:  J Cell Mol Med       Date:  2019-11-03       Impact factor: 5.310

4.  Tetraspanin CD9 promotes the invasive phenotype of human fibrosarcoma cells via upregulation of matrix metalloproteinase-9.

Authors:  Michael J Herr; Jayaprakash Kotha; Nikolaus Hagedorn; Blake Smith; Lisa K Jennings
Journal:  PLoS One       Date:  2013-06-28       Impact factor: 3.240

5.  Colocalisation of CD9 and mortalin in CD9-induced mitotic catastrophe in human prostate cancer cells.

Authors:  V Zvereff; J-C Wang; K Shun; J Lacoste; M Chevrette
Journal:  Br J Cancer       Date:  2007-09-11       Impact factor: 7.640

6.  miR-518f-5p decreases tetraspanin CD9 protein levels and differentially affects non-tumourigenic prostate and prostate cancer cell migration and adhesion.

Authors:  Danielle R Bond; Crystal Naudin; Adam P Carroll; Belinda J Goldie; Joshua S Brzozowski; Helen M Jankowski; Murray J Cairns; Leonie K Ashman; Christopher J Scarlett; Judith Weidenhofer
Journal:  Oncotarget       Date:  2017-12-07

7.  EpCAM-claudin-tetraspanin-modulated ovarian cancer progression and drug resistance.

Authors:  Zehra Tavsan; Hülya Ayar Kayalı
Journal:  Cell Adh Migr       Date:  2020-12       Impact factor: 3.405

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.